Inhibition of the renin-angiotensin system and cardiorenal protection: Focus on losartan and angiotensin receptor blockade

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 11, 2005, Pages 1931-1942

  Parvanova, Aneliya ^a   Chiurchiu, Carlos ^a   Ruggenenti, Piero ^a,b   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Angiotensin II; AT1 receptor blockers; Diabetic and non diabetic nephropathies; Losartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LACIDIPINE; LOSARTAN; TELMISARTAN; TRANDOLAPRIL; URICOSURIC AGENT; VALSARTAN;

ABDOMINAL PAIN; ANGIONEUROTIC EDEMA; ARTICLE; ASTHENIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG POTENTIATION; EDEMA; FATIGUE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HEMATOLOGIC DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASE; LIVER TOXICITY; METABOLIC DISORDER; MICROALBUMINURIA; NAUSEA; NONHUMAN; PATHOGENESIS; PHARMACODYNAMICS; PHARYNGITIS; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR DISEASE; THORAX PAIN; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY FAILURE, CHRONIC; LOSARTAN; RANDOMIZED CONTROLLED TRIALS; RENIN-ANGIOTENSIN SYSTEM;

EID: 25444450810     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.11.1931     Document Type: Article

References (89)

1. XUE JL, MA JZ, LOUIS TA, COLLINS AJ: Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J. Am. Soc. Nephrol. (2001) 12:2753-2758.
2. NATIONAL INSTITUTES OF HEALTH: Excerpts from the United States Renal Data System's 2000 annual data report: atlas of end-stage renal disease in the United States: economic costs of ESRD. Am. J. Kidney Dis. (2000) 36(Suppl. 2):163-176.
3. PARVING H-H: Diabetic nephropathy: prevention and treatment. Kidney Int. (2001) 60(5):2041-2055.
4. KUSSMAN MJ, GOLDSTEIN HH, GLEASON RE: The clinical course of diabetic nephropathy. JAMA (1976) 236:1861-1863.
5. REMUZZI G, BERTANI T: Mechanisms of disease: pathophysiology of progressive nephropathies. N. Engl. J. Med. (1998) 339:1448-1456.
6. ADLER AI, STEVENS RJ, MANLEY SE, BILOUS RW, CULL CA, HOLMAN RR: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. (2003) 63:225-232.
7. BRENNER BM, COOPER ME, DE ZEEUW D, KEANE WF, MITCH WE, PARVING H-H: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. (2001) 345:861-869.
8. LEWIS EJ, HUNSICKER LG, CLARKE WR et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients in nephropathy due to type 2 diabetes. N. Engl. J. Med. (2001) 345:851-860.
9. WEIR MR, DZAU VJ: The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am. J. Hypertens. (1999) 12(Suppl.):205-213.
10. PERICO N, RUGGENENTI P, REMUZZI G: Losartan in diabetic nephropathy. Expert Rev. Cardiovasc. Ther. (2004) 2(4):473-483.
11. UNGER T: The role of the renin-angiotensin system in the development of cardiovascular disease. Am. J. Cardiol. (2002) 89(Suppl.):3A-9A.
12. RUGGENENTI P, AROS C, REMUZZI G: Renin-angiotensin system, proteinuria, and tubulointerstitial damage. Contrib. Nephrol. (2001) 135:187-199.
13. HOSTETTER T, ROSENBERG M, IBRAHIM H, JUKNEVICIUS I: Aldosterone in progressive renal disease. Semin. Nephrol. (2001) 21:573-579.
14. KUMAR D, ZIMPELMANN J, ROBERTSON S, BURNS KD: Tubular and interstitial cell apoptosis in the streptozotocin-diabetic rat kidney. Nephron Exp. Nephrol. (2004) 96: e77-e88.
15. REMUZZI G, RUGGENENTI P, PERICO N: Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann. Intern. Med. (2002) 136:604-615.
16. MASCHIO G, ALBERTI D, JANIN G et al.: Effect of angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. (1996) 334:939-945.
17. GRUPPO ITALIANO DI STUDI EPIDEMIOLOGICI IN NEFROLOGIA (GISEN): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet (1997) 349:1857-1863.
18. RUGGENENTI P, PERNA A, GHERARDI G, GASPARI F, BENINI R, REMUZZI G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial: Gruppo italiano di studi epidemiologici in nefrologia (GISEN): Ramipril Efficacy in Nephropathy. Lancet (1998) 352:1252-1256.
19. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. (1993) 329:1456-1462.
20. RAVID M, SAVIN H, JUTRIN I, BENTAL T, KATZ B, LISHNER M: Long-term stabilizing effect of angiotensin-converting-enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann. Intern. Med. (1993) 118:577-581.
21. RAVID M, BROSH D, LEVI Z, BAR-DAYAN Y, RAVID D, RACHMANI R: Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann. Intern. Med. (1998) 128:982-988.
22. LEBOVITZ HE, WIEGMANN TB, CNAAN A et al.: Renal effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int. (1994) 45(Suppl.): 150-155.
23. NIELSEN FS, ROSSING P, GALL MA, SKØTT P, SMIDT UM, PARVING HH: Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes (1997) 46:1182-1188.
24. AHMAD J, SIDDIQUI MA, AHMAD H: Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care (1997) 20:1576-1581.
25. RUGGENENTI P, FASSI A, PARVANOVA A et al.: Preventing Microalbuminuria in Type 2 Diabetes. N. Engl. J. Med. (2004) 351(19):1941-1951.
26. TSUTSUMI Y, MATSUBARA H, MASAKI H et al.: Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilatation. J. Clin. Invest. (1999) 104:925-935.
27. SILVESTRE J-S, TAMARAT R, SENBONMATSU T et al.: Antiangiogenic effect of Angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. Circ. Res. (2002) 90:1072-1079.
28. VERMA S, STRAUSS M: Angiotensin receptor blockers and myocardial infarction. Br. Med. J. (2004) 329:1248-1249.
29. FERRARIO CM, JESSUP J, CHAPPELL MC et al.: Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation (2005) 111:2605-2610.
30. FERRARIO C, ABDELHAMED AI, MOORE M: AII antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan. Curr. Med. Res. Opin. (2004) 20(3):279-293.
31. RAYNER B: Advances in the treatment of diabetic renal disease: focus on losartan. Curr. Med. Res. Opin. (2004) 20(3):333-340.
32. REMUZZI G, PERICO N, SANGALLI F et al.: ACE inhibition and ANG II receptor blockade improve glomerular-size selectivity in IgA nephropathy. Am. J. Physiol. (1999) 276:F457-F466.
33. KEDZIORA-KORNATOWSKA K: Effect of angiotensin converase inhibitors and AT1 angiotensin receptor antagonists on the development of oxidative stress in the kidney of diabetic rats. Clinica Chimica Acta (1999) 287:19-27.
34. DEVEREUX RB, DAHLOF B, KJELDSEN SE et al.: Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann. Intern. Med. (2003) 139:169-177.
35. NIELSEN S, DOLLERUP J, NIELSEN B et al.: Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrol. Dial. Transplant. (1997) 12(Suppl. 2):19-13.
36. TOTO R, SHULTZ P, RAIJ L et al.: Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Hypertension (1998) 31:684-691.
37. HOLDAAS H, HARTMANN A, BERG KJ, LUND K, FAUCHALD P: Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Nephrol. Dial Transplant. (1998) 13:3096-3102.
38. PRAGA M, ANDRADE CF, LUÑO J et al.: Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Nephrol. Dial. Transplant. (2003) 18:1-8.
39. DEL CASTILLO D, CAMPISTOL JM, GUIRADO L et al.: Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int. (1998) 68(Suppl.):135-139.
40. LAVERMAN GD, HENNIING RH, DE JONG PE, NAVIS G, DE ZEEUW D: Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am. J. Kidney Dis. (2001) 38:1391-1384.
41. ANDERSON S, TARNOW L, ROSSING P, HANSEN BV, PARVING HH: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int. (2000) 57:601-606.
42. ANDERSEN S, JACOBSEN P, TARNOW L, ROSSING P, JUHL TR, PARVING HH: Time course of antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. Nephrol. Dial. Transplant. (2003) 18:293-297.
43. JACOBSEN P, TARNOW L, CARSTENSEN B, HOVIND P, POIRIER O, PARVING H-H: Genetic variation in the renin-angiotensin system and progression of diabetic nephropathy. J. Am. Soc. Nephrol. (2003) 19:2843-2850.
44. ANDERSEN S, TARNOW L, CAMBIEN F et al.: Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Kidney Int. (2002) 62:192-198.
45. ANDERSEN S, POSSING P, JUHL TR, DEINUM J, PARVING H-H: Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol. Dial. Transplant. (2002) 17:1413-1418.
46. LACOURCIERE Y, BELANGER A, GODIN C et al.: Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int. (2000) 58:762-769.
47. TAN KC, CHOW WS, AI VH et al.: Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria. Diabetes Metab. Res. Rev. (2002) 28:71-76.
48. DE PABLOS-VELASCO PL, PAZOS TORAL F, ESMATJES JE et al.: Losartan titration versus diuretic combination in type 2 diabetic patients. J. Hypertens. (2002) 20:715-719.
49. ZANDBERGEN AAM, BAGGEN MGA, LAMBERTS SWJ, BOOTSMA AH, DE ZEEUW D, OUWENDIJK RJT: Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. Ann. Intern. Med. (2003) 139:90-96.
50. PARVING HH, LEHNERT H, BRÖCHNER-MORTENSEN J, GOMIS R, ANDERSEN S, ARNER P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. (2001) 345:870-878.
51. REMUZZI G, RUGGENENTI P, PERNA A et al.: Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J. Am. Soc. Nephrol. (2004) 15(12):3117-3125.
52. CHAN JCN, WAT NMS, SO W-Y et al.: Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL study. Diabetes Care (2004) 27:874-879.
53. KEANE WF, BRENNER BM, DE ZEEUW D et al.: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. (2003) 63:1499-1507.
54. BARNET AH, BAIN SC, BOUTER P et al.: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N. Engl. J. Med. (2004) 351:1952-1961.
55. OTS M, MACKENZIE HS, TROY JL, RENNKE HG, BRENNER BM: Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J. Am. Soc. Nephrol. (1998) 9:224-230.
56. RUSSO D, MINUTOLO R, PISANI A: Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am. J. Kidney Dis. (2001) 38:18-25.
57. AGARVAL R: Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int. (2001) 59:2282-2289.
58. CAMPBELL R, SANGALLI F, PERTICUCCI et al.: Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int. (2003) 63:1094-1103.
59. NAKAO N, YOSHIMURA A, MORITA H et al.: Combination treatment of angiotensin-II receptor blocker and angiotensin-convering enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized, controlled trial in Japan. Lancet (2002) 361:117-124.
60. LAVERMAN GD, NAVIS G, HENNING RH, DE JONG PE, DE ZEEUW D: Dual rennin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int. (2002) 62:1020-1025.
61. JACOBSEN P, ANDERSEN S, JENSEN BR, PARVING H-H: Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J. Am. Soc. Nephrol. (2003) 14:992-999.
62. MOGENSEN CE, NELDAM S, TIKKANEN I et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br. Med. J. (2000) 321:1440-1444.
63. KURIYAMA S, TOMONARI H, TOKUDOME G et al.: Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy. Hypertens. Res. (2002) 25:849-855.
64. KIM M-J, SONG JH, SUH JH, LEE SW, KIM GA: Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy. Yonsei Med. J. (2003) 44(3):463-472.
65. TAAL MW, BRENNER BM: Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int. (2000) 57:1803-1817.
66. POURDJABBAR A, PARKER TG, NGUYEN QT et al.: Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: effect of dose on survival, ventricular arrhythmias, function, and remodeling. Am. J. Physiol. Heart Circ. Physiol (2005) 288:H1997-H2005.
67. DAHLOF B, DEVEREUX RB, KJEELDSEN SE et al.: Cardiovascular morbidity and mortality in the Losartan Intervention for endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet (2002) 359:995-1003.
68. IBSEN H, WACHTELL K, OLSEN MH et al.: Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J. Hypertens. (2004) 22:1805-1811.
69. HØIEGGEN A, ALDERMAN MH, KJELDSEN SE et al.: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. (2004) 65:1041-1049.
70. SOWERS JR: Update on the cardiometabolic sindrome. Clin. Cornerstone (2001) 4(2):17-23.
71. OLSEN MH, FOSSUM E, HØIEGGEN A et al.: Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J. Hypertens. (2005) 23:891-898.
72. LITHELL HO: Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care (1991) 14:203-209.
73. LINDHOLM LH, IBSEN H, BORCH-JOHNSEN K et al.: Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J. Hypertens. (2002) 20:1879-1886.
74. WACHTELL K, HORNESTAM B, LEHTO M et al.: Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation. The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J. Am. Coll. Cardiol. (2005) 45:705-711.
75. WACHTELL K, LEHTO M, GERDTS E et al.: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J. Am. Coll. Cardiol. (2005) 45:712-719.
76. DEVEREUX RB, DAHLÖF B, GERDTS E et al.: Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol. The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. Circulation (2004) 110:1456-1462.
77. LINDHOLM LH, IBSEN H, DAHLÖF B et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for End Point Reduction in Hypertension (LIFE): a randomised trial against atenolol. Lancet (2002) 359:1004-1010.
78. LINDHOLM LH, DAHLÖF B, EDELMAN J et al.: Effects of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet (2003) 362:619-620.
79. DE ZEEUW, REMUZZI G, PARVING HH et al.: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 110(8):921-927.
80. PITT B, SEGAL R, MARTINEZ FA et al.: Randomised trail of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet (1997) 349:747-752.
81. PITT B, POOLE-WILSON PA, SEGAL R et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study (ELITE II). Lancet (2000) 355:1582-1587.
82. DICKESTEIN K, KJEKSHUS J: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet (2002) 360:752-760.
83. STRIPPOLI GFM, CRAIG M, DEEKS JJ, SCHENA FP, CRAIG JC: Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. Br. Med. J. (2004) 329:828-839.
84. HERMAN WH, SHAHINFAR S, CARIDES GW et al.: Losartan reduces the costs associated with diabetic end-stage renal disease. Diabetes Care (2003) 26:683-687.
85. AMERICAN DIABETES ASSOCIATION: Standards of medical care for patients with diabetes mellitus. Diabetes Care (2002) 25(Suppl. 1):33-49.
86. HEART OUTCOMES PREVENTION EVALUATION (HOPE) STUDY INVESTIGATORS: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet (2000) 355:253-259.
87. RUGGENENTI P, SCHIEPPATI A, REMUZZI G: Progression, remission, regression of chronic renal diseases. Lancet (2001) 357:1601-1608.
88. ABRASS CK: Overview: obesity: what does it have to do with kidney disease? J. Am. Soc. Nephrol. (2004) 15(11):2768-2772.
89. KURTZ TW: Treating the metabolic syndrome: telmisartan as a peroxisome proliferators-activated receptor-gamma activator. Acta Diabetol. (2005) 42(Suppl. 1):9-16.